GC Medical Science Corporation (KOSDAQ:142280)

Market Cap	122.19B +47.7%
Revenue (ttm)	108.41B +4.4%
Net Income	3.67B +2.4%
EPS	146.00 +256.1%
Shares Out	21.74M
PE Ratio	38.49
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,967,690
Average Volume	4,827,888
Open	4,815.00
Previous Close	4,860.00
Day's Range	4,760.00 - 6,310.00
52-Week Range	3,200.00 - 6,310.00
Beta	0.49
RSI	66.26
Earnings Date	Apr 13, 2026

About GC Medical Science

GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company’s products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer f...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1972
• Employees: 122
• Stock Exchange: KOSDAQ
• Ticker Symbol: 142280

Financial Performance

In 2025, GC Medical Science's revenue was 108.41 billion, an increase of 4.39% compared to the previous year's 103.85 billion. Earnings were 3.67 billion, an increase of 2.38%.